A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin (60 or 200 mg/m2) Compared to Levoleucovorin (60 or 200 mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer

Trial Profile

A Single-Blind, Randomized Phase I/II Study of Pharmacokinetic and Pharmacodynamic Investigation of Modufolin (60 or 200 mg/m2) Compared to Levoleucovorin (60 or 200 mg/m2) in Tumor, Adjacent Mucosa and Plasma for Patients With Colon Cancer

Completed
Phase of Trial: Phase I/II

Latest Information Update: 25 May 2016

At a glance

  • Drugs Folitixorin (Primary) ; Levofolinic acid
  • Indications Colon cancer
  • Focus Pharmacokinetics
  • Sponsors Isofol Medical
  • Most Recent Events

    • 04 Feb 2015 Results published in an Isofol Medical media release.
    • 29 Aug 2013 Status changed from recruiting to completed as reported by European Clinical Trials Database record.
    • 12 Mar 2013 Isofol has received interim results from the first 16 patients, according to a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top